This dual-action mechanism, combining controlled EVE release and the intrinsic mTOR modulatory capabilities of lignin-derived oligomers, may represent a promising “on/off” switch strategy to significantly improve EVE-based cancer therapies, potentially overcoming existing resistance mechanisms and enhancing overall treatment outcomes [18]. This evidence concerns the gene MTOR and cancer.